Merged in December 2004 with Québec-based Neokimia Inc, Tranzyme, Inc. (Tranzyme) had been a biotechnology company engaged in the development of proprietary technologies for applied genomics, proteomics and drug discovery. Tranzymes technology enables the study of gene function and protein expression in the clinically relevant biological systems - a capability critical for successful gene function analysis and for building biological assays for drug discovery. These systems include gene expression in specific cell types and tissues, in explanted organs, and in animal models of disease. Tranzymes goal is to discover and develop new therapeutic lead compounds in partnership with other pharmaceutical and biotechnology companies. In addition, Tranzyme is focused on building an intellectual property portfolio of novel gene function(s) and assembling its own specific gene libraries for drug discovery and development.
